Characterization and control of dsRNA impurities in mRNA products | Unknown Author | ResearchPod

Transcript: Characterization and control of dsRNA impurities in mRNA products

Alex: Welcome to another episode of ResearchPod. Today, we're looking at a specific challenge in modern medicine: how to ensure mRNA vaccines are as pure as possible.

Sam: We're discussing a recent industry report on a manufacturing problem called double-stranded RNA, or dsRNA. To understand it, think about how RNA normally works. A healthy RNA strand is like a single rail of a ladder — it has a specific direction and does a specific job. But during vaccine manufacturing, the process sometimes accidentally creates a second strand that runs in the opposite direction, like a mirror image. These paired, mirror-image strands are what we call dsRNA, and they're an unintended byproduct of the production process.

Alex: So this paper is basically asking how we can stop these "mirror" strands from showing up in the final product?

Sam: Exactly. And the central irony is that the very tool used to build the vaccine — an enzyme called T7 RNA polymerase, which acts like a molecular photocopier — is the same thing that accidentally creates these unwanted strands. Think of it like a factory machine that's supposed to stamp out perfect parts, but occasionally gets confused and stamps them in reverse.

Alex: And the body notices the difference?

Sam: It does, and that's the core problem. Our immune system has an early-warning system — a first line of defense that doesn't need to recognise a specific threat, it just looks for general signs that something foreign has invaded. One of those warning signs is double-stranded RNA, because healthy human cells almost never produce it naturally. So when the body detects it, it assumes a virus is present and triggers an inflammatory response. Scientists call these warning signals "pathogen-associated molecular patterns," or PAMPs.

Alex: So the body sees these PAMPs and thinks it's under attack, which causes inflammation. Why is that so hard to fix?

Sam: Because the impurities aren't all the same. Some are long, some are short, some have different structural shapes. No single test can catch every variation. It's like trying to detect a counterfeit banknote: an automated scanner might miss a sophisticated fake, so you need a multi-step verification process — checking the paper texture, the watermark, and the ink quality — to be certain.

Alex: So you need several different tests, each looking for something slightly different?

Sam: That's the idea, and the technical term for it is an "orthogonal" testing framework. "Orthogonal" just means the methods are independent of each other — they look at the problem from completely different angles, so a flaw that slips past one test is likely to be caught by another. One method might use antibodies that physically latch onto the double-stranded shape. Another might use genetic sequencing to read the actual code of the impurity. By combining them, you get a much clearer picture of what's actually in the vial.

Characterization and control of dsRNA impurities in mRNA products

Unknown Author

Aug 6, 2026·5:56·user_upload

dsRNA impuritiesIn vitro transcription (IVT)Analytical methodsDownstream processingmRNA/LNP productsImmune recognition

Listen

6 min

Briefing

The Challenge of dsRNA in mRNA Manufacturing

Messenger RNA (mRNA) therapeutics have gained significant clinical traction, yet their manufacturing process—specifically in vitro transcription (IVT)—introduces unique challenges. A primary concern is the formation of double-stranded RNA (dsRNA) impurities. Because dsRNA is structurally similar to viral genetic material, it is recognized by the human innate immune system as a pathogen-associated molecular pattern (PAMP). When present in a therapeutic product, these impurities can activate receptors like TLR3 and RIG-I, potentially leading to unwanted inflammatory responses, cytokine production, and reduced protein translation efficiency.

Mechanisms of Formation and Mitigation

dsRNA is not a single, well-defined molecule but a heterogeneous population of RNA duplexes. These form during IVT through several mechanisms, including the RNA polymerase switching to the non-template strand, the folding back of the 3'-end of runoff transcripts, or the annealing of short abortive transcripts to the main mRNA product.

To manage these impurities, manufacturers employ a multi-pronged strategy:

Process Optimization: Adjusting magnesium and nucleotide concentrations to reduce polymerase pausing and secondary structure formation.
Template Quality: Using high-purity, linearized plasmid DNA to minimize templates for aberrant transcription.
Enzyme Engineering: Utilizing mutated RNA polymerases designed to reduce the generation of dsRNA.
Downstream Processing: Implementing purification steps post-IVT to remove dsRNA from the final mRNA product.

Analytical Landscape and Regulatory Expectations

Regulatory agencies emphasize the need for rigorous characterization and control of dsRNA, yet they provide little specific guidance on acceptable thresholds. This is largely because the clinical significance of dsRNA varies by product and therapeutic context. Current analytical methods—ranging from antibody-based assays like ELISA and dot blots to non-antibody-based techniques—often yield inconsistent results. The lack of standardized reference materials further complicates the ability to set universal safety limits, forcing developers to establish product-specific specifications based on their unique manufacturing processes and clinical risk assessments.

Key Terms and Definitions

In Vitro Transcription (IVT) — A cell-free enzymatic process used to synthesize mRNA from a DNA template using RNA polymerase.
Pathogen-Associated Molecular Pattern (PAMP) — A molecular feature, such as dsRNA, that is recognized by the innate immune system as a signal of viral or bacterial infection.
Abortive Transcripts — Short, incomplete RNA fragments generated during the initiation phase of transcription that can act as precursors for dsRNA formation.
Runoff Transcript — The full-length mRNA product generated when the RNA polymerase reaches the end of the DNA template.
Immunogenicity — The ability of a substance to provoke an immune response, which in the context of mRNA products, can be unintentionally enhanced by the presence of dsRNA impurities.

Characterization and control of dsRNA impurities in mRNA products: Research Paper Podcast